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Background: Despite increased life expectancy among patients with cystic ﬁbrosis (CF), few studies have examined coping among adolescents and
young adults with CF. Previous research suggests that stigma associated with chronic disease is related to worse physical and psychological health,
but optimism may be protective. This study examined stigma and optimism among patients with CF.
Methods: Seventy-two patients with CF (ages 14 to 25) completed a self-report questionnaire assessing stigma, distress, CF-speciﬁc quality of life
(QoL), and optimism. Objective health data were recorded from patient medical records.
Results: Greater stigma was associated with lower pulmonary function, QoL, and optimism. Stigma was positively correlated with distress.
Optimism moderated the relationship between stigma and anxiety (p b 0.001), and between stigma and emotional functioning (p b 0.01).
Conclusions: Stigma is related to worse lung function and psychological health in patients with CF, but higher levels of optimism may act as a
protective factor.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Stigma; Optimism; Quality of life; CopingCystic fibrosis (CF) is characterized by both visible and
concealable physical symptoms, a burdensome and time-intensive
treatment regimen, and a shortened life expectancy. However,
medical advances over the past six decades have led to improved
quality of life (QoL) and increased life expectancy, with estimates
approaching 50 years or more for those born with CF in 2000 or
later [1]. As a result, CF has evolved from being viewed as a
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f.V. Ation. However, relatively little is known about how individuals
cope with the disease during adolescence or early adulthood.
Thus, it is important to clarify psychological factors that may
influence adaptation to CF during adolescence and early
adulthood. Of particular interest in the context of adolescent
development is the degree to which stigma associated with CF
may have a negative influence on patient outcomes and whether a
dispositional trait such as optimism may act as a buffer in the
process of coping with CF.
Health-related stigma is a social process in which the
experience or anticipation of negative social judgment based on
a health condition results in social rejection, blame, or devaluation
[2]. Conditions leading to stigma include physical deformities,
showing any physical signs of illness, and belonging to a social
group that results in a “spoiled identity” or undesirable reputationll rights reserved.
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time and the extent to which the characteristic disrupts social
interactions may influence stigma [4]. Previous research in other
medical conditions has consistently found that stigma is related to
increased psychological distress, worse health-related QoL, and
lower self-esteem [5–7]. Although the relationship between
stigma and physical health in medical populations has received
little attention, psychosocial stress has been associated with poor
physical health outcomes in a number of studies [8–10]. Stigma
may be a particularly relevant form of psychosocial stress during
adolescence and early adulthood when sense of identity is
developed, greater independence from parental figures is negoti-
ated, and social comparisons increasingly influence the establish-
ment and maintenance of social relationships.
According to classic definitions of stigmatizing illness [3,4],
CF may be stigmatizing due to visible symptoms (e.g., coughing,
stunted or delayed growth, and taking medications with meals), a
shortened life expectancy, risk for increased comorbidities and
illness severity with increased age, having a genetic abnormality,
and the potential for treatments and symptoms to disrupt normal
functioning or activity. Qualitative data suggest that patients with
CF may feel different from their peers as a result of the daily time
requirements for treatments, which often occur throughout the
day [11]. Consequently, patients may experience increased social
anxiety in social settings [11] or choose to be noncompliant with
their treatments in order to feel similar to their peers [12,13].
Some patients with CF may choose to conceal their diagnosis
from others by attempting to minimize symptoms or hide
medication usage [14]. Despite the relevance of stigma in the
context of CF, no quantitative studies of stigma have been
conducted to date among patients with CF.
Prior studies of adult medical patients have found that the
dispositional trait of optimism may buffer illness-associated
stress [15] because optimism is a personality trait characterized
by a general expectation of favorable outcomes [16]. Past studies
suggest that greater optimism may be associated with better QoL
and less distress among patients with CF. Optimism appears to be
negatively correlated with psychopathology and positively
correlated with QoL, but unrelated to disease severity [17]. In
addition, a coping style characterized by optimistic acceptance
has been associated with better QoL, especially psychosocial
aspects of QoL [18]. Among children and adolescents with CF,
optimism has been negatively related to internalizing symptoms
(e.g., depression), independent of pulmonary function [19]. No
prior study has evaluated the relationship of optimism and stigma
among patients with CF.
The primary aim of this study was to evaluate the relationship
of stigma to psychological and physical health in adolescents and
young adults with CF (ages 14 to 25). Specifically, it was
hypothesized that stigmawould be related to increased symptoms
of depression and anxiety, poorer CF-specific QoL, lower
optimism, and worse physical health as measured by indicators
of illness severity (e.g., pulmonary function, body mass index
(BMI), hospitalizations during the prior six months, number of
medications, and comorbid conditions). A second aim of this
study was to evaluate optimism as a moderator of the relationship
of stigma to psychological distress (e.g., depression, anxiety),CF-specific QoL, and illness severity (i.e., pulmonary function).
It was hypothesized that stigma would be associated with lower
psychological distress, better QoL, and better pulmonary function
in the context of higher optimism. In the context of lower
optimism, stigma was expected to be related to more psycholog-
ical distress, worse QoL, and poorer pulmonary function.
1. Methods
1.1. Participants
Participants were recruited between July 2010 and March
2011 from a large pediatric and adult CF center in the Midwest.
Male and female outpatients were eligible for participation if
they were between the ages of 14 and 25, had a physician's
diagnosis of CF, and had the capacity to give informed consent,
or assent if under 18 years of age. Informed consent was
obtained from a parent or legal guardian if the patient was
under the age of 18.
Recruitment occurred by directly soliciting patients with CF
during their regularly scheduled clinic visits. If interested, the
patient (and parent or legal guardian if under 18) reviewed and
signed the consent form, which granted access to their clinic
medical records. Participants then completed a questionnaire
packet during the clinic visit or online at a later time. The
questionnaire packet required approximately 30 min to complete.
The online format was provided as a convenience to encourage
study participation and prevent the participants from feeling
obligated to complete the questionnaires during the clinic visit.
Follow-up calls were made, as needed, to remind participants
about completing the online questionnaires. Participants received
a $5 gift card for completing the assessment. This study was
approved by the hospital Institutional Review Board.
1.2. Measures
Medical/health data were collected from patient medical
records including BMI, hospitalizations during the prior six
months, number of current medications, number of co-morbid
medical diagnoses, and pulmonary function testing (PFT) results.
Due to the relatively low number of hospitalizations, these data
were coded as a dichotomous variable (yes or no for hospitaliza-
tion in the prior six months). Comorbid diagnoses were identified
by chart review and a summary score was calculated reflecting all
additional medical diagnoses (excluding psychiatric diagnoses).
Pulmonary function was measured with the percent predicted of
forced expiratory volume in the first second (FEV1), measured
during PFT at the clinic visit.
Self-report questionnaires assessed demographic and back-
ground information, as well as the following measures of stigma,
psychological well-being (depression, anxiety, and optimism),
and CF-specific QoL:
1.2.1. Stigma
Perceived and enacted stigma were measured with Fife and
Wright's [5] Social Impact Scale (SIS). This 24-item self-report
scale was developed to assess the impact of stigma among
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multiple dimensions of stigma. This measure is comprised of a
total stigma score and four subscales representing social rejection
(9 items), financial insecurity (3 items), internalized shame (5
items), and social isolation (7 items). Each item is rated on a
four-point Likert scale from 1 (Strongly Disagree) to 4 (Strongly
Agree) and includes a “Not applicable” response option. “Not
Applicable” responses were assigned a score of 1, consistent with
a “Strongly Disagree” response. Higher total scores represent
more experiences or stronger perceptions of being stigmatized.
Three items on the scale were modified to better fit this
population; two items regarding financial insecurity were altered
to incorporate both financial and academic concerns (e.g., “My
job security or academic performance has been affected by my
illness”); and one question from the social rejection subscale was
modified to include “classmates” along with “employer/co-
workers,” for those participants still in school and/or too young to
work. Fife and Wright [5] reported good discriminant validity,
internal consistency, and construct validity for the SIS. In this
sample, Cronbach's α was 0.91 for the total SIS, and α ranged
from 0.63 to 0.87 for the four subscales.
1.2.2. Depression and anxiety
Depression and generalized anxiety were measured using the
Hospital Anxiety and Depression Scale (HADS [20]), a 14-item
self-report measure. The measure includes an anxiety subscale
(HADS-A), and a depression subscale (HADS-D). Each subscale
is composed of seven items that are rated on a 4-point Likert
scale. This is an especially useful tool amongmedical populations
because it limits the confounding of somatic complaints by
excluding somatic symptoms. The HADS has sound psychomet-
ric properties and is considered a reliable measure for detecting
both anxiety and depression in medical populations [20,21]. For
each subscale, a score greater than or equal to eight indicates a
clinical level of anxiety or depression [22]. In this sample,
Cronbach's α was 0.83 for the total HADS scale, 0.78 for the
anxiety subscale, and 0.74 for the depression subscale.
1.2.3. Optimism
Optimism was measured using the Life Orientation Test-
Revised (LOT-R [16,23]), a 10-item self-report measure of
dispositional optimism, with several items reverse scored, four
“filler” items, and responses rated 0 (“I disagree a lot”) to 4 (“I
agree a lot”). Higher scores indicate greater optimism and lower
scores indicate greater pessimism, or the expectation that bad
things will happen [23]. The LOT-R is one of the most widely used
measures of optimism, with good reliability (e.g., internal and test–
retest) and validity (e.g., convergent, discriminant, and predictive
[23]). Internal reliability of the measure in this sample was
acceptable (Cronbach's α = 0.79).
1.2.4. CF-related quality of life
Health-related QoL specific to CF was measured using the
Cystic Fibrosis Questionnaire-Revised (CFQ-R [24]). This
measure was designed specifically for use with CF patients and
has been validated with CF adolescents and adults, ages 14 and
older. It consists of 50 items that are divided into 12 standardizedsubscales, including: physical functioning (8 items), role
functioning (4 items), vitality (4 items), emotional functioning
(5 items), social functioning (6 items), body image (3 items),
eating disturbances (3 items), treatment burden (3 items), health
perceptions (3 items), weight symptoms (1 item), respiratory
symptoms (7 items), and digestion symptoms (3 items). The
weight symptoms, respiratory symptoms, and digestion symp-
toms subscales specifically assess physical symptoms commonly
experienced by patients with CF, while the other nine subscales
address health-related QoL domains. Scores for each subscale
range from 0 to 100 and higher scores indicate better QoL. The
CFQ-R has demonstrated good reliability and validity as a
health-related QoL measure for individuals with CF (age ≥ 14
[24]). Cronbach's α ranged from 0.40 (treatment burden) to 0.92
(physical functioning) for each of the subscales, consistent with
findings from a previous study [24].
1.3. Data analysis
The primary mode of data analysis included correlational
analyses, ANOVA, and hierarchical regression analyses. Corre-
lational analyses were conducted to evaluate the relationship of
stigma with psychological distress (e.g., depression and anxiety),
QoL, optimism, and health outcomes (e.g., BMI, PFT, number of
comorbid diagnoses, and number of medications). ANOVA was
used to evaluate differences in psychological and physical
variables between those with and without hospitalizations in the
prior six months. Hierarchical regression analyses were used to
test moderation effects of optimism in the relationship of stigma
to psychological distress, QoL, and pulmonary function. For each
outcome variable (i.e., psychological distress, QoL, and pulmo-
nary function), stigma was entered in the first step, optimism was
entered in the second step, and the interaction term for stigma and
optimism was entered in the final step. Regression models for
psychological distress and QoL were adjusted for pulmonary
function, but not age or gender since neither patient-level variable
was related to stigma. Analyses were conducted using Statistical
Analysis Software 9.2.
2. Results
Of eighty-one patients who were recruited to participate in the
study (n = 38 females), six patients declined (n = 2 females) due
to lack of interest or time, and seventy-five agreed to participate
in the study. Seventy-two participants returned completed study
packets (non-completers: n = 3 male). Most participants (n = 57,
79%) completed the paper version of the questionnaire during the
clinic visit. Consistent with norms for this medical population,
the sample was 50% female (n = 36), 97% Caucasian (n = 70),
and 3% African American (n = 2). Participants ranged in age
from 14 to 25 (M = 19.1 (3.3)), and had completed an average of
11.5 (2.2) years of education. Objective indicators of health, as
shown in Table 1, include pulmonary function, total number of
medications (including CF-specific medications and non-CF
medications), hospitalizations, and comorbid diagnoses.
Correlational analyses of stigma with measures of physical
health (i.e., BMI, PFT, number of medications, number of
Table 1
Mean (SD) values for all medical and self-report measures.
M (SD) Range
Physical
FEV1% predicted 78.5 (25.4) 28.6–134.2
BMI 20.5 (2.5) 15.1–28.2
# of medications 12.5 (3.6) 4–21
# of comorbid diagnoses 2.6 (1.6) 0–6
# of hospitalizations (past 6 months) 0.8 (1.0) 0–6
Psychological
Total stigma (SIS) 38.7 (11.1) 24–63
Social rejection 13.6 (4.7) 9–24
Financial/Academic insecurity 5.4 (2.4) 3–12
Internalized shame 7.5 (2.4) 5–14
Social isolation 12.0 (4.1) 7–20
Total distress (HADS) 10.0 (6.2) 1–31
Anxiety 6.5 (3.9) 0–21
Depression 3.5 (3.2) 0–11
Optimism (LOT-R) 14.8 (4.4) 2–23
Quality of life (CFQ-R)
Physical functioning 78.3 (22.6) 12.5–100
Role functioning 75.7 (20.4) 25–100
Vitality 55.0 (18.3) 8.3–83.3
Emotional functioning 72.5 (20.8) 0–100
Social functioning 70.8 (19.7) 22.2–100
Body image 67.3 (26.6) 0–100
Eating disturbances 87.9 (19.6) 0–100
Treatment burden 52.4 (19.1) 0–100
Health perception 63.2 (28.6) 0–100
Weight symptoms 47.2 (38.5) 0–100
Respiratory symptoms 62.5 (20.0) 16.7–100
Digestion symptoms 73.7 (24.5) 0–100
Key: FEV1% predicted = the percent of predicted forced expiratory volume in 1 s;
BMI = body mass index; SIS = Social Impact Scale; HADS = Hospital Anxiety
and Depression Scale; LOT-R = Life Orientation Test-Revised; CFQ-R = Cystic
Fibrosis Questionnaire-Revised.
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correlated with pulmonary function, as shown in Table 2.
Lower FEV1% predicted was associated with greater total stigma,
as well as with stigma subscales of social rejection, financial/
academic insecurity, and social isolation. Internalized shame was
not associated with pulmonary function. Stigma and stigma
subscales were not associated with other indicators of physical
health, including hospitalizations during the prior six months.
As observed in recent population-based data from patients
with CF in Germany [7], a larger proportion of participants
scored above the clinical cut-off on the anxiety subscale (n = 25,
34.7%) than the depression subscale (n = 11, 15.3%). Total
stigma was positively correlated with total distress (HADS), as
well as both the anxiety and depression subscales, as shown in
Table 2. Total stigma was also negatively correlated with
optimism (LOT-R). The pattern of significant correlations for
three of the stigma subscales (social rejection, financial/academic
insecurity, social isolation) was similar to correlations for the total
score. Internalized shame was the only stigma subscale not
associated with depression or optimism.
Analysis of QoL data indicated that total stigma was
negatively correlated with 10 of 12 CF-specific QoL subscales
(physical functioning, role functioning, vitality, emotionalfunctioning, social functioning, body image, treatment burden,
health perception, weight symptoms, and respiratory symptoms).
Eating disturbances and digestion symptoms were not associated
with total stigma. The pattern of correlations for three of the
stigma subscales (social rejection, financial/academic insecurity,
social isolation) resembled that of the total score. Internalized
shame was the only stigma subscale not consistently associated
with the CF-specific QoL subscales.
Results of hierarchical regression analyses indicated that
optimism moderated the relationship of stigma with total
distress (t = −2.63, p = 0.01), as shown in Fig. 1. Analysis of
subscales indicated that optimism moderated the relationship
between stigma and anxiety (t = −3.73, p b 0.001), but not
between stigma and depression (t = −0.39, p = 0.70). Results
also indicated a significant interaction of stigma and optimism
for the emotional functioning scale (t = 3.38, p = 0.001), as
shown in Fig. 2. Regression results are summarized in Table 3.
Optimism did not moderate the relationship of stigma to any of
the other QoL subscales or the relationship of stigma with
pulmonary function.
3. Discussion
This is the first study to document quantitatively a relationship
between stigma and indicators of physical health, psychological
functioning, and QoL in adolescents and young adults with CF.
The sample reported QoL (CFQ-R) levels generally consistent
with prior data from patients with mild to moderate CF, with the
exception of weight symptoms and digestion symptoms, which
were lower for this sample [24,25]. Stigma (SIS) scores were
similar to or lower than those reported in other medical populations
[26,27]. These data are consistent with previous research on stigma
in chronically ill populations, revealing that stigma is associated
with increased psychological distress, lower QoL, poorer body
image, lower self-esteem, and a lower sense of personal control
[5,6]. In the current study, stigma also was related to lower levels of
optimism and lower pulmonary function, but was unrelated to
other objective indicators of physical health. The observed
relationship between stigma and pulmonary function provides
objective data consistent with the correlation of stigma with
physical functioning and respiratory symptoms. Because pulmo-
nary functioning is measured routinely during clinic visits for
patients with CF, patients are regularly reminded of their
pulmonary functioning status and may be more aware of this
aspect of their condition than of other physical symptoms. Elevated
awareness of decreased pulmonary function may contribute to a
greater sense of stigmatization. Due to the cross-sectional nature of
this study, the direction of the relationship between stigma and
pulmonary function/symptoms cannot be determined. However,
past data on stigma and physical health has utilized primarily
self-reported physical symptoms rather than objective indicators of
health. Thus, these data provide further concrete evidence of the
relationship between physical health and psychological functioning
among adolescents and young adults with CF.
Although the Internalized Shame subscale of the SIS was
not associated with pulmonary function, depression, optimism,
or with most of the QoL subscales, questions on this subscale
Table 2
Correlation of stigma and stigma subscales with age, physical health, psychological well-being, and quality of life.
Total stigma Social rejection Finan./Academic insecurity Internalized shame Social isolation
Age 0.21 0.13 0.38 ⁎⁎ 0.00 0.19
Physical
FEV1% predicted −0.31 ⁎⁎ −0.33 ⁎⁎ −0.28 ⁎ −0.01 −0.31 ⁎⁎
BMI −0.06 −0.07 −0.07 0.03 −0.05
Medications 0.12 0.06 0.17 0.07 0.08
Comorbid diagnoses 0.02 0.13 −0.03 −0.16 0.04
Psychological
Total distress (HADS) 0.53 ⁎⁎⁎ 0.41 ⁎⁎⁎ 0.49 ⁎⁎⁎ 0.25 ⁎ 0.53 ⁎⁎⁎
Anxiety 0.51 ⁎⁎⁎ 0.39 ⁎⁎ 0.52 ⁎⁎⁎ 0.25 ⁎ 0.47 ⁎⁎⁎
Depression 0.40 ⁎⁎⁎ 0.32 ⁎⁎ 0.32 ⁎⁎ 0.21 0.44 ⁎⁎⁎
Optimism (LOT-R) −0.37 ⁎⁎ −0.30 ⁎ −0.32 ⁎⁎ −0.18 −0.38 ⁎⁎
Quality of life (CFQ-R)
Physical functioning −0.49 ⁎⁎⁎ −0.47 ⁎⁎⁎ −0.40 ⁎⁎⁎ −0.14 −0.48 ⁎⁎⁎
Role functioning −0.46 ⁎⁎⁎ −0.49 ⁎⁎⁎ −0.55 ⁎⁎⁎ −0.05 −0.34 ⁎⁎
Vitality −0.34 ⁎⁎ −0.33 ⁎⁎ −0.43 ⁎⁎⁎ 0.03 −0.30 ⁎
Emotional functioning −0.57 ⁎⁎⁎ −0.40 ⁎⁎⁎ −0.49 ⁎⁎⁎ −0.25 ⁎ −0.65 ⁎⁎⁎
Social functioning −0.58 ⁎⁎⁎ −0.50 ⁎⁎⁎ −0.36 ⁎⁎ −0.43 ⁎⁎⁎ −0.53 ⁎⁎⁎
Body image −0.51 ⁎⁎⁎ −0.49 ⁎⁎⁎ −0.27 ⁎ −0.27 ⁎ −0.54 ⁎⁎⁎
Eating disturbances −0.07 −0.04 −0.08 0.06 −0.13
Treatment burden −0.26 ⁎ −0.18 −0.38 ⁎⁎ −0.13 −0.22
Health perception −0.53 ⁎⁎⁎ −0.48 ⁎⁎⁎ −0.39 ⁎⁎⁎ −0.22 −0.53 ⁎⁎⁎
Weight symptoms −0.28 ⁎ −0.29 ⁎ −0.31 ⁎ −0.16 −0.18
Respiratory symptoms −0.35 ⁎⁎ −0.36 ⁎⁎ −0.43 ⁎⁎⁎ −0.00 −0.30 ⁎
Digestion symptoms −0.14 −0.18 −0.38 ⁎⁎ 0.17 −0.05
Note: Key: FEV1% predicted = the percent of predicted forced expiratory volume in 1 s; BMI = bodymass index; SIS = Social Impact Scale; HADS = Hospital Anxiety
and Depression Scale; LOT-R = Life Orientation Test-Revised; CFQ-R = Cystic Fibrosis Questionnaire-Revised.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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of illness to others. It appears that these aspects of stigma
among patients with CF are not associated with distress or QoL
possibly because the clearly genetic origin of the disease may
minimize self-blame and related fears of illness disclosure.0
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Fig. 1. Distress by level of stigma and optimism. Interaction revealing that
higher stigma and lower optimism were associated with elevated distress. For
purposes of graphing the interaction, high levels of optimism and stigma were
defined as one SD above the mean, while low levels were defined as one SD
below the mean. Key: Distress = Hospital Anxiety and Depression Scale
(HADS); Stigma = Social Impact Scale (SIS); Optimism = Life Orientation
Test-Revised (LOT-R).Consistent with prior studies of other patient groups, optimism
appeared to be a protective factor for emotional functioning,
especially among patients experiencing higher levels of stigma.
The relationship between stigma and distress (especially anxiety)
was more pronounced in the context of lower optimism. Thus,0
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Fig. 2. Emotional functioning by level of stigma and optimism. Interaction
revealing that higher stigma and lower optimism were associated with lower
emotional functioning. For purposes of graphing the interaction, high levels of
optimism and stigmawere defined as one SD above themean, while low levels were
defined as one SD below the mean. Key: Emotional functioning = Emotional
functioning domain of the Cystic Fibrosis Questionnaire-Revised (CFQ-R);
Stigma = Social Impact Scale (SIS); Optimism = Life Orientation Test-Revised
(LOT-R).
Table 3
Hierarchical regression models evaluating optimism as a moderator of the relationship between stigma and psychological distress as well as between stigma and
emotional functioning quality of life.
Dependent variable
HADS total
Predictors Coefficient SE sr2 p Adjusted R2 Model p
1. FEV1% −0.02 0.02 0.00 0.48
Total stigma (SIS) 0.21 0.06 0.13 b0.001
Optimism (LOT-R) −0.58 0.15 0.13 b0.001
0.43 b0.001
2. FEV1% −0.02 0.02 0.01 0.36
Total stigma 0.72 0.20 0.11 b0.001
Optimism 0.83 0.55 0.02 0.13
Stigma ∗ optimism −0.04 0.01 0.06 0.01
0.48 b0.001
HADS anxiety subscale
1. FEV1% 0.01 0.02 0.00 0.58
Total stigma 0.16 0.04 0.16 b0.001
Optimism −0.30 0.10 0.09 0.004
0.37 b0.001
2. FEV1% 0.01 0.01 0.00 0.70
Total stigma 0.60 0.13 0.19 b0.001
Optimism 0.95 0.35 0.06 0.01
Stigma ∗ optimism −0.03 0.01 0.11 b0.001
0.48 b0.001
HADS depression subscale
1. FEV1% −0.03 0.01 0.04 0.06
Total stigma 0.06 0.03 0.04 0.07
Optimism −0.27 0.09 0.10 0.005
0.28 b0.001
2. FEV1% −0.03 0.01 0.05 0.06
Total stigma 0.12 0.12 0.01 0.35
Optimism −0.12 0.34 0.00 0.74
Stigma ∗ optimism −0.00 0.01 0.00 0.66
0.27 b0.001
CFQ-R — emotional functioning subscale
1. FEV1% 0.01 0.08 0.00 0.87
Total stigma −0.83 0.20 0.17 b0.001
Optimism 1.58 0.52 0.09 0.003
0.40 b0.001
2. FEV1% 0.03 0.07 0.00 0.68
Total stigma −2.97 0.65 0.17 b0.001
Optimism −4.38 1.81 0.05 0.02
Stigma ∗ optimism 0.15 0.04 0.09 0.001
0.49 b0.001
Key: FEV1% predicted = the percent of predicted forced expiratory volume in 1 s; SIS = Social Impact Scale; HADS = Hospital Anxiety and Depression Scale;
LOT-R = Life Orientation Test-Revised; CFQ-R = Cystic Fibrosis Questionnaire-Revised; sr2 = squared semi-partial correlation.
742 K.N. Oliver et al. / Journal of Cystic Fibrosis 13 (2014) 737–744higher optimismmay be reflective of patients recognizing but not
internalizing the stigma associated with CF. Although the CF
diagnosis may be viewed as stigmatizing, greater optimism
allows patients to retain a more positive outlook. Lower optimism
and higher stigma may make patients especially vulnerable to
experiencing symptoms of anxiety. Post-hoc analysis indicated
that a contrasting model predicting stigma from the interaction of
anxiety and optimism was not significant. However, due to the
limited inferences that can bemade from correlational data, future
research should further explore the causal direction of the
relationship between stigma and distress, as well as moderating
variables such as dispositional optimism. Interestingly, optimism
did not appear to moderate the influence of physical or socialcorrelates of stigma (e.g., non-emotional CFQ-R subscales).
Optimism may be most likely to influence emotional functioning
in the context of stigma, perhaps reflecting a more direct
association of optimism with emotional states than with physical
states, due to a mediating role of health behavior in the
relationship of optimism and physical function [28]. The
regression analyses for the quality of life measure were conducted
without any statistical correction because the goal of this study
was to fully assess the influence of stigma on a wide range of
quality of life dimensions. However, this resulted in a total of 12
regressions in the analysis of quality of life. Therefore, it is
possible that the significant interaction of stigma and optimism in
predicting emotional functioning occurred by chance.
743K.N. Oliver et al. / Journal of Cystic Fibrosis 13 (2014) 737–744The current study has several limitations including suscep-
tibility to social desirability and response bias because most
measures were self-report. In an attempt to minimize that effect,
participants were reminded that their responses were anony-
mous and that participation was voluntary. More importantly,
participants were informed that participation or refusal to
participate did not affect their usual medical treatment at the
clinic. In addition, it was thought that the online option for
completing study questionnaires would provide a greater sense of
anonymity while enhancing convenience. Although only approx-
imately 20% of our sample chose to complete the questionnaire
online, this may be a useful option for future studies being
conducted in busy clinic settings. Because we did not have
objective or third-party indicators of stigma, emotional function-
ing, or quality of life, it is possible that the present data
under-estimate the degree of distress and discomfort that patients
may experience. Future studies could address this concern with
inclusion of observer ratings. Observer ratings or other measure-
ment methods would also address the potential limitation of
shared method variance, which may have contributed to inflated
or deflated effects in this study. In addition, future research could
address questions of causation by conducting longitudinal follow
up rather than relying on cross-sectional data alone.
By examining the impact of stigma on psychological func-
tioning in adolescents and young adults with CF, this study
identified two factors that are important to consider when working
with patients with CF. Patients experiencing greater stigma
associated with their illness may be at higher risk of psychological
distress and lower QoL. In particular, patients with lower trait
optimism and higher reported stigma may be more likely to
experience distress and may benefit from further psychosocial
assessment or intervention. Increased awareness of stigma may be
important for medical personnel to attend to due to the association
of stigma with poorer physical and psychological functioning
among patients with CF. In addition, greater attention to the
expression of low optimism (i.e., pessimism) among patients with
CF reporting stigmatizing experiences may help identify patients
more likely to experience emotional distress. Because there can be
social discomfort associated with expression of emotional distress
among patients with CF, discussion of stigmatizing experiences
and optimistic/pessimistic views may be helpful as a way to
address factors associated with emotional distress.
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